Sarilumab improves Patient-reported Outcomes in Rheumatoid Arthritis Patients with Inadequate Response/Intolerance to Tumour Necrosis Factor Inhibitors
Strand V, Reaney M, Chen C-I, Proudfoot CWJ, Guillonneau S, Bauer D, Mangan E, Graham NMH, van Hoogstraten H, Lin Y, Pacheco-Tena C, Fleischmann R. - RMD Open 2017;3:e000416. DOI:10.1136/rmdopen-2016-000416
Evidence is presented that treatment with sarilumab demonstrates patient-reported benefits in TNF-IR patients with moderate to severe RA. These improvements complement the clinical efficacy previously reported for sarilumab, and are consistent with those seen in the MOBILITY trial (MTX-IR patients)1, yet in a more difficult-to-treat population.
Data were analysed from the 24-week Phase 3 TARGET randomised controlled trial in adult patients with active RA and previous inadequate response or intolerance to ≥1 TNF inhibitor. Patients received subcutaneous placebo or sarilumab 150 mg or 200 mg every 2 weeks in combination with csDMARDs, for 24 weeks.
PROs assessed were: Patient Global Assessment of Arthritis (PtGA), Pain, HAQ-DI, the
Short-Form [SF]-36 domains (physical functioning, role physical, bodily pain, general health perceptions, vitality, social functioning, role emotional, and mental health), fatigue, household work productivity and participation in family/social activities, morning stiffness, and the effect of RA on patients’ lives.
Both doses of sarilumab in combination with csDMARDs resulted in clinically meaningful patient-reported benefits at 12 and 24 weeks with respect to pain, fatigue, function, participation and health status, which exceeded placebo plus csDMARDs.
1. Strand V, et al. Arthritis Res Ther 2016;18:198.